ReviewNature reviews. Rheumatology2014
Interstitial lung disease in connective tissue disease--mechanisms and management.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Serum KL-6 and the mortality of patients with connective tissue disease-associated interstitial lung disease: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: a systematic review and meta-analysis of cohort studies.Frontiers in medicine · 2024Pooled it
- Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.Seminars in arthritis and rheumatism · 2021Pooled it
- Cyclophosphamide for connective tissue disease-associated interstitial lung disease.The Cochrane database of systematic reviews · 2018Pooled it
- Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.Rheumatology (Oxford, England) · 2024Trial
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Real-World Data on Halting Radiographic Progression with Antifibrotics in Connective Tissue Disease-Associated Interstitial Lung Disease: A Two-Center Study from Hungary.Journal of clinical medicine · 2026Article
- Early detection and risk stratification in autoimmune-related interstitial lung disease: a state-of-the-art review.Respiratory research · 2026Review
- Targeted next-generation sequencing of bronchoalveolar lavage fluid for pathogen detection in connective tissue disease-related pulmonary infections.Microbiology spectrum · 2026Article
- Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.Frontiers in immunology · 2026Review
- The immune dysregulation of fibrosis: insights into immune-fibrotic crosstalk and potential therapeutic targets.Frontiers in immunology · 2026Review
- To B or Not to B: Germinal Center Responses in Progressive Fibrotic Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- [Connective tissue disease-associated interstitial lung diseases : A pattern-based approach to diagnosis].Radiologie (Heidelberg, Germany) · 2025Review
- Evaluation of patients diagnosed with primary Sjogren's syndrome with and without pulmonary involvement.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Assessing Lung Involvement in Paediatric Rheumatic Diseases: A Retrospective Evaluation of the Limitations of Spirometry.Mediterranean journal of rheumatology · 2025Article
- Connective tissue disease-associated interstitial lung disease: an approach to treatment amidst an expanding evidence base.Internal medicine journal · 2025Review
- Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis.Journal of visualized experiments : JoVE · 2025Article
- Assessing pulmonary vascular remodeling in connective tissue disease-associated interstitial lung disease: a CT-based quantitative analysis.Quantitative imaging in medicine and surgery · 2025Article
- The lung microbiome in interstitial lung disease.Breathe (Sheffield, England) · 2025Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pulmonary complications are an important extra-articular feature of autoimmune rheumatic diseases and a major cause of mortality. The underlying pathogenesis probably involves multiple cellular compartments, including the epithelium, lung fibroblasts, and the innate and adaptive immune system. Heterogeneity in the extent and progression of lung fibrosis probably reflects differences in underlying pathogenic mechanisms. Growing understanding of the key pathogenic drivers of lung fibrosis might lead to the development of more effective targeted therapies to replicate the treatment advances in other aspects of these diseases. Interstitial lung disease (ILD) in connective tissue disease (CTD) is characterized using the classification of the idiopathic interstitial pneumonias. Systemic sclerosis is most frequently associated with ILD and, in most of these patients, ILD manifests as a histological pattern of nonspecific interstitial pneumonia. Conversely, in rheumatoid arthritis, the pattern of ILD is most often usual interstitial pneumonia. The key goals of clinical assessment of patients with both ILD and CTD are the detection of ILD and prognostic evaluation to determine which patients should be treated. Data from treatment trials in systemic sclerosis support the use of immunosuppressive therapy, with the treatment benefit largely relating to the prevention of progression of lung disease.
Indexed as
Identifiers
25266451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.